The PreVAIL-kIds Common Protocol

PreVAIL-kIds 通用协议

• 批准号: 10872420
• 负责人: CARL E ALLEN
• 金额: $ 314.83万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10872420
• 关键词: Advanced Development; Algorithms; Antibodies; Biological Assay; Biological Markers; Biosensor; Black race; Blood; Burn injury; COVID-19; Cells; Child; Childhood; Classification; Clinical; Clinical Data; Communities; DNA; Data; Data Set; Detection; Development; Device Approval; Devices; Diagnosis; Diagnostic; Disease; Emergency Situation; Environment; Face; Flow Cytometry; Frequencies; Generations; Goals; Grant; Health; Inflammatory; Laboratories; Machine Learning; Methods; Michigan; MicroRNAs; Molecular Profiling; Mucocutaneous Lymph Node Syndrome; Nucleic Acids; Pathway interactions; Peptides; Phase; Physicians; Plasma; Process; Prognosis; Proteins; Proteomics; Protocols documentation; RADx Radical; Risk; Route; Saliva; Sampling; Serum; Signal Transduction; Site; Surveys; Swab; Syndrome; Vial device; Viral; Vision; Whole Blood; Work; accurate diagnosis; aptamer; cytokine; data exchange; exome; genetic variant; human coronavirus; instrument; machine learning classification; member; multiplex assay; nanobodies; novel; nuclease; pandemic disease; point of care testing; portability; pressure; prognostic; programs; protein biomarkers; response; severe COVID-19; spatiotemporal; transcriptome sequencing; transcriptomic profiling; treatment optimization; usability

Abstract PreVAIL-kIds sites have iden5fied opportuni5es to rapidly acquire and share samples and clinical data among themselves, thus catalyzing the process of mul5-site valida5on of their ongoing developmental assays and algorithms. Via a survey conducted in April 2023, the sites have iden5fied the matrix of shareable/usable samples and data amongst members of the network. Over 80% of possible exchanges are going to be frui8ul. The goal of this supplemental applica5on is therefore to facilitate the rapid exchange of data/samples between the 8 PreVAIL-kIds sites, so that mul5-site valida5on of their respec5ve assays and algorithms can proceed.

摘要 PreVAIL-kIds研究中心已确定了快速获取和共享样本和临床数据的艾德机会 他们之间，从而催化他们正在进行的发展的多位点验证过程， 分析和算法。通过2023年4月进行的一项调查，这些网站已经确定了艾德 在网络的成员之间共享/可用的样本和数据。超过80%的可能交换是 会是水果。因此，此补充应用程序的目标是促进快速交换 8个PreVAIL-kIds位点之间的数据/样本，因此其各自检测试剂的多位点有效性， 算法可以继续进行。